Text Size

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01625143
First received: June 17, 2012
Last updated: June 19, 2012
Last verified: June 2012
History of Changes

June 17, 2012
June 19, 2012
June 2012
August 2012   (final data collection date for primary outcome measure)
Cellular origins of relapse and the underlying epigenetic mechanisms associated with drug resistance [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01625143 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
Molecular Taxonomy of Pediatric Cancer

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia.

OBJECTIVES:

  • To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL).
  • To identify specific transcription factor-binding sites associated with histone alterations.
  • To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications.

OUTLINE: Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Leukemia
  • Genetic: RNA analysis
  • Genetic: gene expression analysis
  • Genetic: microarray analysis
  • Genetic: nucleic acid sequencing
  • Genetic: polymerase chain reaction
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
Not Provided
August 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of B-cell acute lymphoblastic leukemia

    • Paired diagnosis-relapse primary patient samples obtained from the Children's Oncology Group (COG) cell bank

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
up to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01625143
CDR0000735342, COG-AALL12B7
Not Provided
Peter C. Adamson, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: William L. Carroll, MD NYU Clinical Cancer Center
National Cancer Institute (NCI)
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP